June 2009

Last Word

May 25, 2009

Madeira Therapeutics’ Peter Joiner Presents a Case for the Pediatric Market In the pediatric setting, I believe that Madeira as well as others committed to this arena have the responsibility of educating physicians as to how a drug should be used and what role it plays in a patient’s life. Peter Joiner is CEO and […]

Talent Pool

May 25, 2009

Pharmaceutical POOL Kurt HARTMAN Dr. Craig HOPKINSON New Hires at Eisai Eisai Inc., a U.S. pharmaceuti cal subsidiary of Japan’s Eisai Co. Ltd., has appointed Kurt Hart man, J.D., senior director of value and access, with responsibility for integrating and aligning Eisai’s focus on reimbursement support services, as well as pricing and contracting strategy. Previ […]

E-Media

May 25, 2009

Symyx Grants ACCESS TO MOLECULE INFORMATION The Biotechnology Industry Organization (BIO) has launched the BIO Community (community.convention.bio.org) to provide free resources to biotechnology leaders and professionals in an effort to help them overcome the chal lenges currently facing the industry. The BIO Community grants individuals access to free podcasts,articles, the BIO event planner,and the BIOConvention […]

What’s New

May 25, 2009

Vincent Aurentz, executive VP of portfolio devel opment, says this activity complements the compa ny’s tool kit of collaborative approaches to build a highquality portfolio with partners. “The creation of a venture capital fund under lines our commitment to be a best partner for biotech entrepreneurs and their investors,”he says. Merkle has created a formal […]

PharmaTrax

May 25, 2009

Pharma R&D Spending Remains Robust Despite Tough Economy Despite the current economic downturn, pharmaceutical research and development spending continues to play a vital role in the pharmaceutical industry. According to a recent report by CBR Pharma Insights, recent trends indicate a consolidation of efforts through numerous acquisitions, both intra-pharmaceutical as well as purchases of biotechs […]

Manufacturer Windfall Rebates: Change on the Horizon

May 25, 2009

The transfer of drug coverage for the dual eligible beneficiaries from Medicaid to Medicare Part D has come under scrutiny by Congress for alleged profit windfalls for manufacturers. The implications of the windfall issue for the pharmaceutical industry are vast. Manufacturers with a large Medicare book of business need to be mindful of this — […]

“Obamaceuticals:” The Good, The Bad, The Controversial, and the Undecided

May 25, 2009

According to the Deloitte 2009 Industry Outlook report published in December 2008, the Obama Administration could make more changes to the nation’s healthcare system than have occurred since the 1960s. While there are many government policy changes proposed, PharmaVOICE asked leaders from all segments of the industry to share their opinions on only a few […]

PharmaOutlet

May 25, 2009

You are planning an upcoming investigators meeting. Going over your checklist, you check off sponsor, project manager, central laboratory, site coordinators, site monitors, principal investigators, and others involved in the research. Flights, hotel accommodations, and meals also have been arranged. So what, if anything, is missing? Have you considered including a representative from the independent […]

ACRP 2009 Wrap Up

May 25, 2009

ACRP 2009 Global Conference & Exhibition — Denver, April 24-28 A record crowd of about 3,000 attended the Association of Clinical Research Professionals (ACRP) 2009 Global Conference & Exhibition in Denver in April. Held in conjunction with the Academy of Pharmaceutical Physicians and Investigators (APPI) Program for the fourth straight year, the event’s theme was […]

David Brennan: Into the Future

May 25, 2009

BY KIM RIBBINK Into the FUTURE In April, the Pharmaceutical Research and Manufacturers of America (PhRMA) elected AstraZeneca CEO David Brennan as its new chairman, a choice that bodes well for the future of health care and the pharmaceutical companies the organization represents. In his more than three decades in the industry, Mr. Brennan has […]

Mastering Multichannel Marketing

May 25, 2009

BY ROBIN ROBINSON KEY TO SUCCESS:Match up channel properties and consistent content with consumer preferences. The key to successful multichannel marketing is to be wherever the consumer is when he or she is ready to receive your message. Easy, right? Not a chance, especially when the consumer is a busy physician or a patient with […]

Annual DIA Preview Showcase

May 25, 2009

SPECIAL FEATURE DIA 45TH ANNUAL MEETING We all share in the responsibility to work together to strengthen the science used in pharmaceutical product development, evaluation, and review,” says Program Chair Nancy Smith, Ph.D., former director of the Office of Training and Communications, CDER, at the U.S. Food and Drug Administration. “We must find new tools […]

Meet the Chief Scientific Officers

May 23, 2009

The CSO Role The chief scientist officer helps set a company’s strategy, interacts with investors and board of directors, and helps people understand the science behind new products. MCKERNAN. PFIZER. A CSO at Pfizer handles everything from the idea to proof of concept, establishing and building a portfolio and help ing the molecule transfer into […]

Upfront

May 23, 2009

UPFRONT Milestones 20TH ANNIVERSARY John R. Vogel Associates Inc. celebrates 20 years of assisting pharmaceutical and biopharmaceutical companies and the pharmaceutical service providers to enhance results achieved through outsourcing and strategic alliances. Mr. Vogel, who founded the company in Oldwick, N.J., relocated in 2001 to Wailea, Hawaii. The consultancy conducts onsite training on outsourcing and […]

Letter from the Editor

May 23, 2009

Could the tide be turning? The bad and the good We know we are operating in a new economic frontier, when bad news actually passes for good news. A recently released IMS report states that the value of the global pharmaceutical market is expected to grow 2.5% to 3.5% on a constant-dollar basis in 2009, […]

FEEDBACK